Healthcare & Life Sciences Private Equity Deal Tracker: Sixth Street Leads $830 Million Investment Into Caris Life Sciences

McGuireWoods LLP
Contact

Sixth Street has led an $830 million growth equity investment into Caris Life Sciences, according to a news release.

Caris, based in Irving, Texas, develops molecular profiling assays for oncology that scan DNA, RNA and proteins to reveal a molecular blueprint intended to help physicians and patients make more precise and personalized cancer treatment decisions.

Sixth Street, based in San Francisco, is a global investment firm. Founded in 2009, the firm’s healthcare and life sciences team provides strategic growth capital tailored to healthcare and pharma business timelines including to develop or launch new medicines, make asset acquisitions and fund strategic projects.

Silver Lake, Fidelity Management & Research Company and Coatue were significant participants in the Caris funding round. Additional investors included Columbia Threadneedle Investments, Canada Pension Plan Investment Board, Millennium Management, Neuberger Berman Funds, Highland Capital Management, Rock Springs Capital, OrbiMed, ClearBridge Investments, Tudor Investment Corp., Eaton Vance Equity (Morgan Stanley), Pura Vida Investments and First Light Asset Management.

Caris indicated in the release that it intends to use the funding for commercial expansion and investment toward delivering a liquid biopsy platform with high concordance to tissue across different modalities, including therapy selection, recurrence monitoring and early screening across all cancer types.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McGuireWoods LLP | Attorney Advertising

Written by:

McGuireWoods LLP
Contact
more
less

McGuireWoods LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.